菌群研创平台
Search documents
江苏集萃药康生物科技股份有限公司2025年度业绩快报公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2026-02-03 22:38
Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 793.25 million RMB, an increase of 15.49% compared to the previous year [1] - The net profit attributable to the parent company was 144.40 million RMB, reflecting a 31.49% increase year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 118.01 million RMB, showing a significant increase of 55.80% [1] - Total assets at the end of the reporting period were 2,872.76 million RMB, up 11.67% from the beginning of the period [1] - Equity attributable to the parent company increased by 4.44% to 2,229.50 million RMB [1] Operational Performance Factors - The company focused on internationalization and innovation as core strategies, expanding overseas markets and maintaining high R&D investment to stay at the forefront of technology and products [2] - Revenue growth was driven by an expanding sales network covering North America, Europe, and Asia-Pacific, leading to increased customer numbers and brand recognition [2] - Domestic revenue growth was supported by improved industry conditions and increased R&D investments from downstream industrial clients, resulting in a notable recovery in demand [2]